Nemaura Medical (OTC:NMRD) touted precision data today from the on-going European clinical trial program of its non-invasive, needle-free glucose monitoring system, sugarBeat.
The study included 16 patients with Type I and Type II diabetes. The participants wore two sugarBeat skin-patches simultaneously over 3 days for up to 14 hours each day.
The trial showed that more than 80% of the data between the two skin-patches at each time point were within 8% of each other.
Results from the precision trial provide concrete validation of the sugarBeat system, the company said.
“The precision study for sugarBeat has exceeded our expectations and is a significant milestone towards commercial launch,” CEO Faz Chowdhury said in prepared remarks.
Nemaura’s on-going clinical trial program in Europe is slated to finish later this month and the company said it hopes to launch sugarBeat in the U.K. in early 2018.
